[Lab] split one vial across Medutest and Janoshik — 96.2% and 99.2%
I have had 19 orders now and I keep a table, so here is the honest summary rather than a vibe.
Material has been consistent. Communication has not. Shipping has varied by about 32 days on nominally the same lane, which matters more in summer than in February.
The independent number came back 99.0% against a claimed 99.1%, which I read as agreement rather than a discrepancy — inter-lab variance on this assay is a point or two either way and treating one lab as ground truth is how people end up in pointless arguments with vendors.
Batch number is in the comments. Ask if you want the method.
best — the order this archive was captured in
Mechanistically the bit that matters is triple agonist. It explains most of the early profile and a decent chunk of the outcome.
The glucagon component does different things than dual agonism. The fatigue are not just amplified versions.
No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.
phase 2 numbers are not maintenance numbers, cite the trial
nobody should be giving this to anyone without extensive monitoring
This is correct. Triple agonism is genuinely different.
Dose escalation on retatrutide is steeper and faster than on semaglutide. Do not assume the titration patterns transfer.
nobody should be giving this to anyone without extensive monitoring
Which trial arm and what was the n?
phase 2 numbers are not maintenance numbers, cite the trial
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
TRIUMPH data is phase 2, not phase 3, smaller n and shorter
This is correct. Triple agonism is genuinely different.
Dose escalation on retatrutide is steeper and faster than on semaglutide. Do not assume the titration patterns transfer.
Disagree but this is the good kind of wrong — it is specific enough to be checked.
What was the dosing schedule in that arm?
[removed by moderator]
the 2.5mg arm is different from 5mg, results do not transfer
triple agonism is phase 2, do not generalise
[removed by moderator]
Adding to this: dose escalation is doing more work than the comment implies.
the weight curves are unusually steep, which makes predicting individual response harder
research use only, handling and analysis, not protocols
The confident tone is doing a lot of work that the evidence is not.
The confident tone is doing a lot of work that the evidence is not.
Adding to this: triple agonist is doing more work than the comment implies.
research use only, handling and analysis, not protocols
Respectfully this is a sample of one presented as a finding.
Respectfully this is a sample of one presented as a finding.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
the glucagon component changes the side effect profile, not just the efficacy
retatrutide is not approved anywhere for human use, posts must not read as instructions
- 1What was the dosing schedule in that arm?14 comments in this branch · started by u/helga_vermeulen
- 2This is correct. Triple agonism is genuinely different.8 comments in this branch · started by u/yannick_salinas